Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Janux Therapeutics Inc (NASDAQ: JANX) closed at $45.06 down -3.64% from its previous closing price of $46.76. In other words, the price has decreased by -$3.64 from its previous closing price. On the day, 1.33 million shares were traded. JANX stock price reached its highest trading level at $46.18 during the session, while it also had its lowest trading level at $42.0.
Ratios:
For a deeper understanding of Janux Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 38.80 and its Current Ratio is at 38.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 07 ’25 when Campbell David Alan sold 5,000 shares for $60.00 per share. The transaction valued at 300,004 led to the insider holds 293,054 shares of the business.
Campbell David Alan bought 5,000 shares of JANX for $300,004 on Jan 07 ’25. On Jan 02 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 13,334 shares for $54.88 each. As a result, the insider received 731,785 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2741671168 and an Enterprise Value of 1730136960. For the stock, the TTM Price-to-Sale (P/S) ratio is 199.57 while its Price-to-Book (P/B) ratio in mrq is 3.59. Its current Enterprise Value per Revenue stands at 132.588 whereas that against EBITDA is -20.626.
Stock Price History:
The Beta on a monthly basis for JANX is 3.26, which has changed by 3.8255935 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $7.79. The 50-Day Moving Average of the stock is -17.04%, while the 200-Day Moving Average is calculated to be -5.77%.
Shares Statistics:
For the past three months, JANX has traded an average of 1.07M shares per day and 1177280 over the past ten days. A total of 52.34M shares are outstanding, with a floating share count of 46.79M. Insiders hold about 19.04% of the company’s shares, while institutions hold 78.43% stake in the company. Shares short for JANX as of 1734048000 were 6414759 with a Short Ratio of 7.15, compared to 1731628800 on 4185628. Therefore, it implies a Short% of Shares Outstanding of 6414759 and a Short% of Float of 19.520001.
